Denali Therapeutics (NASDAQ:DNLI) Stock Breaks Above 50-Day Moving Average – Here’s What Happened

Denali Therapeutics Inc. (NASDAQ:DNLI) passed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $20.35 and traded as high as $22.19. Denali Therapeutics shares last traded at $20.96, with a volume of 4,900,052 shares traded.

Trending Headlines about Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: AVLAYAH generated $17.8 million in net product revenue in its second full commercial quarter. Denali expects Q4 revenue of $30 million to $32 million, signaling a sharp sequential increase. Denali Q3 2026 results and business highlights
• Positive Sentiment: Analyst actions were supportive: Morgan Stanley raised its target to $42 and maintained an Overweight rating; Wedbush raised its target to $24 and maintained Outperform; BTIG reaffirmed Buy with a $39 target. These views indicate optimism, though targets are not guarantees. Morgan Stanley research ratings
• Neutral Sentiment: Denali reported $70.1 million in Q3 net income, but that figure included a $194 million one-time gain from the voucher sale. The company ended the quarter with $1.0 billion in cash, cash equivalents and marketable securities. Denali Q3 2026 results and business highlights
• Neutral Sentiment: The company has several potential catalysts ahead, including a planned 2027 BLA submission for zafinofusp and data expected in 2027 from five TransportVehicle programs. These remain development-stage opportunities and carry execution risk. Denali Q3 2026 results and business highlights
• Negative Sentiment: HC Wainwright’s 2027 quarterly forecasts still project losses, ranging from $0.60 per share in Q1 to $0.53 in Q4, underscoring continued costs and the need for sustained product growth. Denali Therapeutics analyst coverage

Wall Street Analysts Forecast Growth

DNLI has been the topic of a number of recent research reports. Robert W. Baird set a $34.00 target price on Denali Therapeutics in a research note on Friday, August 7th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. UBS Group increased their price objective on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Wall Street Zen upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Denali Therapeutics in a research report on Monday, July 13th. They issued an “overweight” rating and a $29.00 price objective on the stock. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $36.15.

Denali Therapeutics Stock Up 7.8%

The stock’s 50-day moving average is $20.35 and its 200-day moving average is $21.25. The stock has a market cap of $3.35 billion, a P/E ratio of -12.12 and a beta of 1.08. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.64. The company had revenue of $17.78 million for the quarter, compared to the consensus estimate of $12.67 million. During the same quarter last year, the firm posted ($0.74) earnings per share. As a group, research analysts anticipate that Denali Therapeutics Inc. will post -2.70 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Alexander O. Schuth sold 2,857 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total transaction of $71,624.99. Following the transaction, the insider owned 281,763 shares in the company, valued at $7,063,798.41. This trade represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 9.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Denali Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Alps Advisors Inc. boosted its stake in Denali Therapeutics by 32.0% during the 3rd quarter. Alps Advisors Inc. now owns 211,772 shares of the company’s stock valued at $4,377,000 after purchasing an additional 51,394 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Denali Therapeutics in the 3rd quarter worth $169,000. VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in shares of Denali Therapeutics by 237.8% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 48,300 shares of the company’s stock worth $998,000 after buying an additional 34,000 shares in the last quarter. Manchester Capital Management LLC raised its stake in shares of Denali Therapeutics by 5,505.6% in the 3rd quarter. Manchester Capital Management LLC now owns 2,018 shares of the company’s stock worth $42,000 after buying an additional 1,982 shares in the last quarter. Finally, E. Ohman J or Asset Management AB grew its holdings in Denali Therapeutics by 3.1% during the third quarter. E. Ohman J or Asset Management AB now owns 165,000 shares of the company’s stock worth $3,411,000 after acquiring an additional 5,000 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.